ethyl 3-amino-3-(pyridin-3-yl)propionate hydrochloride | 163919-14-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl 3-amino-3-(pyridin-3-yl)propionate hydrochloride
• 英文别名: ethyl (+/-)-3-amino-3-(3-pyridyl)propanoate hydrochloride；ethyl 3-amino-3-(3'-pyridyl)propionate hydrochloride；ethyl-3-amino-3-(3-pyridyl)propanoate HCl；ethyl rac-3-amino-3-pyridin-3-yl-propionate hydrochloride；Ethyl 3-amino-3-(3-pyridyl)propionate hydrochloride；ethyl 3-amino-3-pyridin-3-ylpropanoate;hydrochloride
• CAS: 163919-14-0
• 化学式: C₁₀H₁₄N₂O₂*ClH
• 分子量: 230.694
• InChiKey: OHXQJZIBASKGJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.46
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  65.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 3-amino-3-(pyridin-3-yl)propionate hydrochloride 在 potassium carbonate 作用下， 以 水 为溶剂， 生成 Ethyl-3-amino-3-(3'-pyridyl)-propionat
  参考文献：
  名称：

  Burkholderia cepacia lipase is an excellent enzyme for the enantioselective hydrolysis of β-heteroaryl-β-amino esters

  摘要：

  The enantioselective (E > 200) lipase PS-catalysed hydrolysis of beta-heteroaryl-beta-amino esters is described. The reactions were performed with H2O (0.5 equiv) in either diisopropyl ether or tert-butyl methyl ether at 25 degrees C. The resulting beta-heteroaryl-substituted beta-amino acid enantiomers were formed in high enantiomeric excess (ee >= 97%) and in good yield (>= 40%). (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.06.019
• 作为产物：
  描述：

  (RS)-3-氨基-3-(3-吡啶基)-丙酸 以 乙醇 为溶剂， 生成 ethyl 3-amino-3-(pyridin-3-yl)propionate hydrochloride
  参考文献：
  名称：

  Heterocyclic glycyl &bgr;-alanine derivatives

  摘要：

  本发明涉及一类由化学式I表示的化合物，或其药学上可接受的盐，包含这类化合物的药物组合物以及治疗由αvβ3整合素介导的疾病的方法。

  公开号：

  US06689754B1

文献信息

• Quinolizinones as integrin inhibitors
  申请人：Biochem Pharma, Inc.

  公开号：US06630488B1

  公开（公告）日：2003-10-07

  The present invention is directed towards novel compounds that are effective inhibitors of integrins, particularly &agr;IIb&bgr;3 or &agr;v integrins such as &agr;v&bgr;3 and &agr;v&bgr;5. One embodiment of the present invention comprises a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. R1, R2, R3, and R4 are defined herein.

  本发明涉及一种新型化合物，它们是有效的整合素抑制剂，特别是αIIbβ3或αv整合素，如αvβ3和αvβ5。本发明的一个实施例包括式(I)或式(II)的化合物，或其药学上可接受的盐、溶剂或代谢前体。R1、R2、R3和R4在此处被定义。
• Platelet aggregation inhibitors
  申请人：G. D. Searle & Co.

  公开号：US05272162A1

  公开（公告）日：1993-12-21

  This invention relates to compounds having the following formula ##STR1## or a pharmaceutically acceptable salt thereof which are useful in the inhibition of platelet aggregation, to pharmaceutical compositions including the compounds and to a method of inhibiting platelet aggregation in mammals by administering such compounds and compositions.

  这项发明涉及具有以下结构式##STR1##或其药学上可接受的盐的化合物，这些化合物在抑制血小板聚集方面是有用的，还涉及包括这些化合物的药物组合物以及通过给予这些化合物和组合物来抑制哺乳动物血小板聚集的方法。
• Thiazole derivatives
  申请人：Hoffman-La Roche Inc.

  公开号：US06100282A1

  公开（公告）日：2000-08-08

  Compounds of the formula: as well as pharmaceutically usable salts and esters thereof, wherein R.sup.1, R.sup.2 and R.sup.3 have the significance ascribed herein, inhibit binding of adhesive proteins to the surface of different types of cell and accordingly influence cell--cell and cell-matrix interactions. These compounds can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumor metastasing, tumor growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure, as well as infection caused by viruses, bacteria or fungi.

  该公式化合物及其药用盐和酯，其中R.sup.1、R.sup.2和R.sup.3具有本文所述的意义，抑制粘附蛋白质与不同类型细胞表面的结合，从而影响细胞间和细胞-基质相互作用。这些化合物可用作药物制剂，用于控制或预防肿瘤、肿瘤转移、肿瘤生长、骨质疏松症、帕金森病、糖尿病视网膜病变、黄斑变性、血管介入后再狭窄、牛皮癣、关节炎、纤维化、肾功能衰竭，以及由病毒、细菌或真菌引起的感染。
• [EN] COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE<br/>[FR] COMPOSITIONS ET MÉTHODES POUR ÉVALUER LE SYSTÈME VASCULAIRE DE L'ŒIL
  申请人：MEDIBEACON INC

  公开号：WO2016183351A1

  公开（公告）日：2016-11-17

  The present disclosure relates to compositions and methods for assessing blood vessels and organs of the body, more specifically to methods for assessing the vasculature of the eye.

  本公开涉及用于评估人体血管和器官的组合物和方法，更具体地说是用于评估眼部血管的方法。
• Substituted heterocyclic derivatives useful as platelet aggregation
  申请人：Monsanto Company

  公开号：US05254573A1

  公开（公告）日：1993-10-19

  Novel substituted heterocyclic derivatives are provided which inhibit platelet aggregation. This invention also pertains to pharmaceutical compositions and methods of using such derivatives.

  提供了一种替代的新型杂环衍生物，可以抑制血小板聚集。该发明还涉及制药组合物和使用这些衍生物的方法。